Standigm agrees partnership with KIST to discover a new drug for Autism

Updated:

Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.

Tags: AI-driven drug discovery , Artificial intelligence , Autism , KIST , Standigm

Categories: News